Product Description
Barnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Barnidipine)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Italy | Korea | Netherlands | Peru | Portugal | Spain | Taiwan | Thailand
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ND | P4 |
Terminated |
Hypertension |
2007-11-06 |
2022-03-12 |
Treatments |
|
| ND | P4 |
Completed |
Hypertension |
2007-01-30 |
2022-03-12 |
Treatments |
|
| 2005-004288-47 | P4 |
Active, not recruiting |
Hypertension |
None |
2022-03-12 |
Treatments |